Compare BLDP & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLDP | ALT |
|---|---|---|
| Founded | 1979 | 1997 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 657.3M | 573.8M |
| IPO Year | 2009 | 2005 |
| Metric | BLDP | ALT |
|---|---|---|
| Price | $1.58 | $2.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | $3.38 | ★ $17.11 |
| AVG Volume (30 Days) | 2.3M | ★ 3.3M |
| Earning Date | 11-16-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $14.39 | N/A |
| Revenue Next Year | $38.94 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $1.43 | $2.00 |
| 52 Week High | $6.57 | $6.44 |
| Indicator | BLDP | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 34.29 | 25.35 |
| Support Level | N/A | N/A |
| Resistance Level | $2.25 | $3.35 |
| Average True Range (ATR) | 0.08 | 0.13 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 36.25 | 6.14 |
Ballard Power Systems Inc is engaged in design, development, manufacture, sale and service of proton exchange membrane ("PEM") fuel cell products for a variety of applications, focusing on power products for bus, truck, rail, marine, stationary and emerging market (material handling, off-road and other) applications, as well as the delivery of services, including technology solutions, after sales services and training. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. Key geographical revenue is derived from United States followed by Poland, Canada, and other countries.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.